Oxaprozin potassium is an orally active and potentCOXinhibitor, withIC₅₀values of 2.2 μM for human plateletCOX-1and and 36 μM for IL-1-stimulated human synovial cellCOX-2, respectively. Oxaprozin potassium also inhibits the activation ofNF-κB. Oxaprozin potassium induces cellapoptosis. Oxaprozin potassium shows anti-inflammatory activity. Oxaprozin potassium-mediated inhibition of theAkt/IKK/NF-κBpathway contributes to its anti-inflammatory properties^[1][2].

Oxaprozin (0-100 μM) induces apoptosis in a dose-dependent manner. Oxaprozin increases caspase-3 activity in the activated but not in the resting condition. NF-κB activation is inhibited by Oxaprozin (50 μM). Oxaprozin inhibits activation of the IKK system induced by the reagent IκBα^[1].
Oxaprozin (100 μM) induces the strongest proapoptotic effect and significantly increases CD40L-treated monocyte apoptosis. Oxaprozin treatment inhibits CD40L-induced Akt and NF-κB (p65) phosphorylation^[2].

331.41

C₁₈H₁₄KNO₃

174064-08-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.